Business Models & Investment Subcommittee


The Business Models & Investment Subcommittee strives to:

  • Map out the manufacturing process and considerations as they relate to optimizing the Business Model, including reimbursement and adoption into standard of care, for both autologous and allogeneic cell therapy products.

Projects and Objectives

  • The  Business Models & Investment Subcommittee will collect information from ISCT stakeholders via online surveys to assist in the development of educational webinars, white papers and roadmaps to support decision-making in cell therapy manufacturing.



Committee Chair


Bill Milligan
Steminent Biotherapeutics Inc.
Vancouver, BC, Canada 

Patrick Rivers, MBA

Aquilo Capital
San Francisco, CA, United States


Committee Members


Matthew Durdy, MBA
Cell and Gene Therapy Catapult
London, England

Suzanne Farid, PhD
University College London
London, England

Brian Hawkins, PhD
BioLife Solutions
Bothwell, WA, United States

Brad King, MBA
Cook Regentec
Indianapolis, IN, United States

Aletta Schnitzler, PhD
Bedford, MA, United States

Sarah Martin
Terumo BCT
Denver, CO, United States
Michael May
Toronto, ON, Canada

Jennifer Moody, PhD
Blue Rock Therapeutics
Toronto, ON, Canada

Charles Mooney
Oklahoma Blood Institute
Oklahoma City, OK, United States

Benjamin Nelson, MBA
Fresenius Kabi
Lake Zurich, IL, United States

Colin Lee Novick
CJ Partners Inc
Tokyo, Japan

Olaf Zoellner, PhD
BD BioSciences
San Jose, CA, United States

Allen Chen, PhD

© 2019 ISCT. All rights reserved. 
ISCT, and the ISCT logo are registered trademarks of the International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of the International Society for Cellular Therapy.

ISCT Privacy Policy